Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Degarelix (Primary) ; Buserelin; Goserelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ProComD
- Sponsors Ferring Pharmaceuticals
- 21 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2016 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
- 21 Apr 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2020.